Literature DB >> 18390717

Inter-strain tissue-infiltrating T cell responses to minor histocompatibility antigens involved in graft-versus-host disease as determined by Vbeta spectratype analysis.

Jenny Zilberberg1, Danielle McElhaugh, Loise N Gichuru, Robert Korngold, Thea M Friedman.   

Abstract

Lethal graft-vs-host disease (GVHD) can be induced between MHC-matched murine strains expressing multiple minor histocompatibility Ag differences. In the B6->BALB.B model, both CD4(+) and CD8(+) donor T cells can mediate lethal GVHD, whereas in the B6->CXB-2 model, only CD8(+) T cells are lethal. TCR Vbeta CDR3-size spectratyping was previously used to analyze CD8(+) and CD4(+) T cell responses in lethally irradiated BALB.B and CXB-2 recipients, which showed significant overlap in the reacting repertoires. However, CD4(+) T cells exhibited unique skewing of the Vbeta2 and 11 families in only BALB.B recipients. These Vbeta family reactivities were confirmed by immunohistochemical staining of lingual epithelial infiltrates, and by positive and negative selection Vbeta family transfer experiments for GVHD induction in BALB.B recipients. We have now extended these studies to examine the T cell repertoire responses involved in target tissue damage. Infiltrating B6 host-presensitized CD8(+) and CD4(+) T cells were isolated 8-10 days post-transplant from the spleens, intestines and livers of CXB-2 and BALB.B transplant recipients. For both T cell subsets, the results indicated overlapping tissue skewings between the recipients, also between the tissues sampled within the respective recipients as well as tissue specific responses unique to both the BALB.B and CXB-2 infiltrates. Most notably, the CD4(+) Vbeta 11(+) family was skewed in the intestines of BALB.B but not CXB-2 recipients. Taken together, these data suggest that there are likely to be target tissue-related anti-multiple minor histocompatibility Ag-specific responses in each of the strain recipients, which may also differ from those found in peripheral lymphoid organs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18390717      PMCID: PMC2613568          DOI: 10.4049/jimmunol.180.8.5352

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Uneven tissue distribution of minor histocompatibility proteins versus peptides is caused by MHC expression.

Authors:  P Griem; H J Wallny; K Falk; O Rötzschke; B Arnold; G Schönrich; G Hämmerling; H G Rammensee
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

Review 2.  Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.

Authors:  Shimon Slavin; Shoshana Morecki; Lola Weiss; Reuven Or
Journal:  J Hematother Stem Cell Res       Date:  2002-04

3.  Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens.

Authors:  R Korngold; P J Wettstein
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

4.  Infusion of select leukemia-reactive TCR Vbeta+ T cells provides graft-versus-leukemia responses with minimization of graft-versus-host disease following murine hematopoietic stem cell transplantation.

Authors:  A E Patterson; R Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

5.  Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens.

Authors:  Thea M Friedman; Stephen C Jones; Debbie Statton; George F Murphy; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2004-04       Impact factor: 5.742

6.  Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens.

Authors:  M de Bueger; A Bakker; J J Van Rood; F Van der Woude; E Goulmy
Journal:  J Immunol       Date:  1992-09-01       Impact factor: 5.422

7.  Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.

Authors:  Stephen C Jones; Thea M Friedman; George F Murphy; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2004-02       Impact factor: 5.742

8.  Differences in MHC-class I presented minor histocompatibility antigens extracted from normal and graft-versus-host disease (GVHD) mice.

Authors:  M Bruley Rosset; V Tieng; D Charron; A Toubert
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

9.  Role of mast cells in early epithelial target cell injury in experimental acute graft-versus-host disease.

Authors:  G F Murphy; H Sueki; C Teuscher; D Whitaker; R Korngold
Journal:  J Invest Dermatol       Date:  1994-04       Impact factor: 8.551

10.  Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease.

Authors:  P J Martin; J A Hansen; B Torok-Storb; L Moretti; O Press; R Storb; E D Thomas; P L Weiden; E S Vitetta
Journal:  Bone Marrow Transplant       Date:  1988-09       Impact factor: 5.483

View more
  7 in total

1.  Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.

Authors:  Sudipto Ganguly; Duncan B Ross; Angela Panoskaltsis-Mortari; Christopher G Kanakry; Bruce R Blazar; Robert B Levy; Leo Luznik
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

2.  Alloimmune response results in expansion of autoreactive donor CD4+ T cells in transplants that can mediate chronic graft-versus-host disease.

Authors:  Dongchang Zhao; James S Young; Yu-Hong Chen; Elizabeth Shen; Tangsheng Yi; Ivan Todorov; Peiguo G Chu; Stephen J Forman; Defu Zeng
Journal:  J Immunol       Date:  2010-12-13       Impact factor: 5.422

3.  Treatment with GM-CSF secreting myeloid leukemia cell vaccine prior to autologous-BMT improves the survival of leukemia-challenged mice.

Authors:  Jenny Zilberberg; Thea M Friedman; Glenn Dranoff; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-12       Impact factor: 5.742

4.  Unraveling graft-versus-host disease and graft-versus-leukemia responses using TCR Vβ spectratype analysis in a murine bone marrow transplantation model.

Authors:  Stacey L Fanning; Jenny Zilberberg; Johann Stein; Kristin Vazzana; Stephanie A Berger; Robert Korngold; Thea M Friedman
Journal:  J Immunol       Date:  2012-11-30       Impact factor: 5.422

5.  Recipient-specific T-cell repertoire reconstitution in the gut following murine hematopoietic cell transplant.

Authors:  Pingping Zheng; John Tamaresis; Govindarajan Thangavelu; Liwen Xu; Xiaoqing You; Bruce R Blazar; Robert S Negrin; James L Zehnder; Bettina P Iliopoulou; Everett H Meyer
Journal:  Blood Adv       Date:  2020-09-08

6.  Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.

Authors:  Marilène Binsfeld; Yves Beguin; Ludovic Belle; Eléonore Otjacques; Muriel Hannon; Alexandra Briquet; Roy Heusschen; Pierre Drion; Jenny Zilberberg; Bjarne Bogen; Frédéric Baron; Jo Caers
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

7.  Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance.

Authors:  Patricia E de Almeida; Everett H Meyer; Nigel G Kooreman; Sebastian Diecke; Devaveena Dey; Veronica Sanchez-Freire; Shijun Hu; Antje Ebert; Justin Odegaard; Nicholas M Mordwinkin; Thomas P Brouwer; David Lo; Daniel T Montoro; Michael T Longaker; Robert S Negrin; Joseph C Wu
Journal:  Nat Commun       Date:  2014-05-30       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.